GlycoMimetics Form 4: Director Receives 9k Stock Options

Rhea-AI Filing Summary

On June 23, 2025, GlycoMimetics, Inc. (GLYC) director David Charles Lubner filed a Form 4 reporting the grant of 9,023 non-qualified stock options at an exercise price of $15.30 per share. The options were acquired for $0.00 and will vest in full on the earlier of June 23, 2026 or the company’s next annual shareholder meeting, subject to continued board service. They carry a 10-year term, expiring June 23, 2035, and are held directly by the director. No open-market purchases, sales, or dispositions of common shares were reported. The filing represents a routine equity-compensation award and does not convey new information about GlycoMimetics’ operating performance, strategy, or near-term cash flows.

Positive

• Routine option grant gives the director a long-term incentive without immediate dilution and signals continued board engagement.

Negative

• None.

Insights

Corporate Governance Expert

TL;DR: Routine option grant; aligns director incentives; immaterial to valuation.

The Form 4 discloses a standard board compensation action—granting 9,023 options to Director Lubner at $15.30. Vesting occurs in roughly one year or sooner at the next AGM, which is customary for small-cap biotech boards. The award size is modest and there are no concurrent stock sales, mitigating governance concerns about insider profit-taking. Because the transaction is a grant, not a disposal, it has no direct market-supply effect. Investors should view the filing as procedural rather than a signal of management sentiment or forthcoming catalysts.

Portfolio Manager

TL;DR: Neutral event; does not alter GLYC risk-reward profile.

From a portfolio perspective, the 9k-share option grant is too small to influence float or liquidity. The $15.30 strike is typically set at or above recent trading levels to encourage long-term value creation, which is shareholder-friendly. However, without accompanying purchases of common shares, the filing lacks predictive power about near-term price movements. I classify the news as non-impactful to earnings estimates or cash runway considerations common to development-stage biotechs.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lubner David Charles

(Last) (First) (Middle)

C/O/ CRESCENT BIOPHARMA, INC.

300 FIFTH AVENUE

(Street)

WALTHAM MA 02451

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
GLYCOMIMETICS INC [ CBIO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/23/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$15.3	06/23/2025		A		9,023		(1)	06/23/2035	Ordinary Shares	9,023	$0.00	9,023	D

Explanation of Responses:

1. This option represents a right to purchase shares of the Issuer's ordinary shares and vests in full on the earlier of (i) June 23, 2026 or (ii) the date of the Issuer's next annual meeting of shareholders, in each case, subject to the Reporting Person's continued service to the Issuer.

	/s/ Barbara Bispham, as attorney-in-fact for David Charles Lubner	06/23/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did GlycoMimetics (GLYC) disclose in the latest Form 4?

Director David Lubner received 9,023 stock options at a $15.30 strike price; no shares were bought or sold.

When will the newly granted GLYC options vest?

They vest in full on the earlier of June 23, 2026 or the company’s next annual shareholder meeting.

What is the expiration date of the GLYC director’s options?

The options expire on June 23, 2035, giving a 10-year exercise window.

Did the filing report any sale of GLYC common stock?

No. The Form 4 only reports an option grant; there were no dispositions of common shares.

How many GLYC derivative securities does Director Lubner now own?

After the grant, he beneficially owns 9,023 derivative securities, all held directly.